See the DrugPatentWatch profile for combigan
Is Combigan Approved for Ocular Hypertension?
Yes, Combigan (brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution) is FDA-approved for treating elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It lowers IOP by reducing aqueous humor production and increasing outflow.[1]
How Does Combigan Work for Ocular Hypertension?
Combigan combines an alpha-2 adrenergic agonist (brimonidine) and a beta-blocker (timolol). Brimonidine decreases aqueous production and enhances uveoscleral outflow; timolol primarily reduces production. Studies show it reduces IOP by 7-9 mmHg on average in ocular hypertension patients, often more effectively than either drug alone.[1][2]
Who Can Use Combigan for This Condition?
It's indicated for adults with ocular hypertension who respond inadequately to beta-blockers alone. Use one drop in each affected eye twice daily, at least 12 hours apart. Not for children under 2 or those with asthma, severe COPD, bradycardia, heart block, or hypersensitivity.[1]
What Are Common Side Effects?
Patients report allergic conjunctivitis (15%), eye redness (10%), burning/stinging (10%), and blurred vision. Systemic effects like dry mouth or fatigue occur less often. Avoid if pregnant or breastfeeding without doctor advice.[1][2]
How Does It Compare to Other IOP-Lowering Drops?
| Treatment | Key Mechanism | Typical IOP Drop | Dosing |
|-----------|---------------|------------------|--------|
| Combigan | Dual (alpha agonist + beta-blocker) | 7-9 mmHg | Twice daily |
| Latanoprost (Xalatan) | Prostaglandin analog | 8-9 mmHg | Once daily |
| Dorzolamide (Trusopt) | Carbonic anhydrase inhibitor | 4-6 mmHg | Three times daily |
| Tafluprost (Zioptan) | Prostaglandin analog | 7-8 mmHg | Once daily |
Combigan suits patients needing stronger dual action but requires more frequent dosing than prostaglandins.[2]
When Does the Combigan Patent Expire?
Core patents expired in 2013, with some formulation patents lasting until 2027-2028. No authorized generics yet; check DrugPatentWatch.com for litigation updates and ANDA filings.[3]
[1] Combigan Prescribing Information, Allergan (AbbVie), 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021534s019lbl.pdf
[2] European Glaucoma Society Terminology and Guidelines, 2021. https://www.eugs.org/eng/egs_guidelines4.asp
[3] DrugPatentWatch.com, Combigan Patent Status. https://www.drugpatentwatch.com/p/tradename/COMBIGAN